Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Paliperidone is primarily eliminated renally (possibly OCT), with minimal metabolism occurring via CYP2D6 and 3A4. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters and have no inhibitory or inducing effects on CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with paliperidone. However, the product label for rilpivirine indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Paliperidone has a possible risk of QTc prolongation and/or TdP on the CredibleMeds.org website.